10x Genomics Announces Its Chromium Single Cell Gene Expression And Xenium In Situ Platforms Were Used In A Publication, Featured On The Cover Of Cancer Cell, Shedding Light On The Role Of Fibrotic Scars In Glioblastoma Treatment Recurrence
10x Genomics Announces Its Chromium Single Cell Gene Expression And Xenium In Situ Platforms Were Used In A Publication, Featured On The Cover Of Cancer Cell, Shedding Light On The Role Of Fibrotic Scars In Glioblastoma Treatment Recurrence
In the September 9 cover article of Cancer Cell, researchers integrated 10x single cell and spatial technologies to identify a mechanism of glioblastoma recurrence in mice and develop a promising potential therapeutic approach.
在9月9日的《癌细胞》封面文章中，研究人员整合了10倍单细胞和空间技术，以确定小鼠胶质母细胞瘤复发的机制，并开发出一种前景看好的潜在治疗方法。
PLEASANTON, Calif., Sept. 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that its Chromium Single Cell Gene Expression and Xenium In Situ platforms were used in a publication – featured on the cover of Cancer Cell – that sheds light on the role of fibrotic scars in glioblastoma treatment recurrence. The study, led by researchers in the laboratory of Professor Johanna Joyce (University of Lausanne, Switzerland) and the Ludwig Institute for Cancer Research (Lausanne, Switzerland), also showcased how inhibiting both colony stimulating factor 1 receptor (CSF-1R; a therapeutic target under investigation for treating multiple cancers, including glioblastoma (GBM)) and the formation of fibrotic scars led to improved survival of mice in preclinical trials.
加利福尼亚州普莱森顿，2024年9月10日 /PRNewswire/--单细胞和空间生物学领域的领导者10x Genomics, Inc.（纳斯达克股票代码：TXG）今天宣布，其Chromium单细胞基因表达和Xenium In Situ平台被用于一本出版物，该出版物刊登在《癌细胞》封面上，该出版物揭示了纤维化疤痕在胶质母细胞瘤治疗复发中的作用。这项研究由约翰娜·乔伊斯教授（瑞士洛桑大学）实验室和路德维希癌症研究所（瑞士洛桑）的研究人员领导，还展示了抑制菌落刺激因子1受体（CSF-1R；正在研究的用于治疗包括胶质母细胞瘤（GBM）在内的多种癌症的治疗靶标）和纤维化疤痕的形成如何提高了临床前试验中小鼠的存活率。
